Engineered nanoparticles have the potential to revolutionize the diagnosis and treatment of
many diseases; for example, by allowing the targeted delivery of a drug to particular subsets …

Antitumor monoclonal antibodies have shown clinical promise as cancer cell surface
targeting agents. More tumor targeting antibodies are likely to be approved by the FDA in the …

Several monoclonal antibodies that target cell surface receptors have gained approval by
the US Food and Drug Administration and are widely used in the treatment of some cancers …

To establish efficient and reliable therapeutic delivery into cancer cells, a number of delivery
agents and concepts have been investigated in the recent years. Among many …

S using a combination of agents. While the late 1940s and 1950s were characterized by
single agent chemotherapy de-INCE CHEMOTHERAPY beginnings 50 years ago by Farber …

The phage display technology is based on the presentation of peptide sequences on the
surface of virions of bacteriophages. Its development led to creation of sophisticated systems …

A new type of high avidity binding molecule, termed “peptabody” was created by harnessing
the effect of multivalent interaction. A short peptide ligand was fused via a semi-rigid hinge …

E-selectin is an inducible cell adhesion molecule which mediates rolling of neutrophils on
the endothelium, an early event in the development of an inflammatory response. Inhibition …

Phage display is a nanotechnology with limitless potential, first developed in 1985 and still
awaiting to reach its peak. Awarded in 2018 with the Nobel Prize for Chemistry, the method …

We previously described the use of a phage-displayed library of random hexapeptides to
define and localise the epitope on the human tumor suppressor protein p53 recognised by …